Drug Database
AM

amphotericin B (Amphotec / Amphocil / ABCD)

✓ Approved

Therametrics · Small Molecule · Small Molecule

What is amphotericin B?

amphotericin B is a small molecule developed by Therametrics. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

Brand NamesAmphotec, Amphocil, ABCD
CompanyTherametrics
Drug ClassSmall Molecule
RouteInjectable (Others), Intravenous (IV)
StatusApproved
Sources: ClinicalTrials.gov, Therametrics

Therapeutic Indications

amphotericin B is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsWound infection fungal✓ Approved

Related Research Articles

PubMediScience2026-08-30

Single-cell transcriptomic signatures of T cells associated with rituximab responsiveness in idiopathic nephrotic syndrome.

Koshi-Ito Eri E, Watanabe Yu Y, Onogi Chikao C, Horinouchi Asuka A et al.

Rituximab (RTX) is increasingly used in steroid-dependent minimal change disease, a leading cause of idiopathic nephrotic syndrome (INS), yet predictors of response remain unclear. Although RTX primarily targets B cells, T cells are also implicated in INS pathogenesis. We investigated RTX-induced T cell dynamics by single-cell RNA sequencing/T cell receptor profiling of peripheral T cells from three responders and three non-responders before and after RTX treatment. Responders exhibited RTX-driven broad transcriptomic remodeling, accompanied by reduced exhausted CD8+ T cells and clonal expansion of CD4+ cytotoxic T cells with enhanced oxidative phosphorylation (OXPHOS) signatures, whereas non-responders showed marginal changes. In a separate cohort, reactive oxygen species (ROS) levels tended to be higher in responders, and declined post-RTX, collectively associating enhanced mitochondrial activity with favorable response. Reanalysis of childhood INS data supported altered B-T cell crosstalk and T cell metabolism. Together, T cells may influence RTX responsiveness, warranting further biomarker studies.

PMID 42668630
Read full article →
PubMedSoft matter2026-08-30

A strategy for preparing porous polymeric micro-/nanomaterials via polymerization-induced self-assembly with process conditions modulated by macromolecular chain transfer agents.

Zhang Furui F, Zhou Xuanxuan X, Zou Yingyi Y, Xu Weishao W et al.

A strategy for the fabrication of porous polymeric micro-/nanomaterials via reversible addition-fragmentation chain transfer (RAFT) polymerization-induced self-assembly (PISA) has been proposed. The process is regulated by tuning the stepwise addition strategy of the macromolecular chain transfer agent (macro-CTA). A systematic study was carried out on three types of polymerization-induced self-assembly (PISA) systems, including redox-initiated and photo-initiated aqueous emulsion polymerization of glycidyl methacrylate (GlyMA), as well as thermally initiated dispersion polymerization of styrene (St) in methanol. All systems were mediated by the same poly(ethylene glycol) methacrylate (PPEGMA) macro-CTA. Experimental results show that all three polymerization-induced self-assembly systems can successfully prepare porous polymer micro-/nanomaterials with regular morphology, tunable pore size, and abundant pores, namely PPEGMA9.1-b-PGlyMAn and PPEGMA9.1-b-PSn. It should be noted that the redox and thermal systems are comprehensively characterized by kinetic and GPC tests, while the photoinitiated system only acts as a supporting demonstration based on TEM images in the supplementary information. Moreover, the process conditions for achieving porous morphologies were explored by adjusting the molar ratio of the macro-CTA added in batches, the time intervals between additions, and the monomer concentration.

PMID 42669414
Read full article →
PubMedRevista espanola de medicina nuclear e imagen molecular2026-08-30

Duration of levothyroxine discontinuation and pre-radioiodine TSH levels in thyroid cancer.

Mintegui G G, Martínez Z Z, Basantes M M, Ferrando R R

Radioiodine treatment in differentiated thyroid carcinoma requires elevated TSH levels to optimize the uptake of [131I]NaI. Levothyroxine suspension is the usual strategy for inducing endogenous TSH elevation, although the optimal duration of this suspension remains controversial. To evaluate the effect of the duration of levothyroxine suspension on TSH levels achieved prior to radioiodine treatment. Retrospective cohort study that included 104 patients with differentiated thyroid carcinoma treated at a reference university center. Patients were classified according to the time of discontinuation of levothyroxine prior to radioiodine treatment: three weeks (group A, n = 21) and four weeks (group B, n = 83). TSH levels between groups and their distribution by categories (<30, 30-49, 50-69, 70-99 y ≥100 mIU/L) were analyzed. The proportion of patients who reached the recommended TSH threshold (≥30 mIU/L) was also evaluated. The mean age (SD) was 46.7 (10.3) years and 87 patients were women. The mean TSH was 70.9 mIU/L (95% CI: 54.5-87.2) in group A and 88.7 mIU/L (95% CI: 84.8-92.6) in group B. The proportion of patients who achieved TSH ≥ 30 mIU/L was significantly higher in group B (100% vs 76.2%; p < 0.001). The distribution of TSH levels by category differed significantly between both groups (p < 0.001). On the other hand, the proportion of patients with TSH ≥ 100 mIU/L did not show significant differences (60.2% vs 47.6%; p = 0.42). In multivariate analysis adjusted for age, sex, and radioiodine dose, levothyroxine discontinuation time was not independently associated with the likelihood of TSH ≥ 100 mIU/L. Three weeks of levothyroxine suspension allowed TSH levels ≥30 mIU/L to be reached in most patients, although a proportion did not reach the recommended threshold. Four weeks were associated with adequate TSH elevation in all patients in this cohort. TSH monitoring during preparation could allow for more individualized strategies that optimize thyroid stimulation, minimizing unnecessary exposure to hypothyroidism.

PMID 42669345
Read full article →
PubMedPatient preference and adherence2026-08-30

Oral Health Behavior Management in Patients with Periodontitis: A COM-B-Guided Qualitative Study.

Bao Jianuo J, Li Yuan Y, Zhang Lei L, Li Shuying S et al.

This study aimed to explore barriers and support needs related to oral health behaviors among patients with periodontitis guided by the Capability-Opportunity-Motivation-Behavior (COM-B) model in a Chinese clinical context. Semi-structured qualitative interviews were conducted with 17 patients diagnosed with stage II-IV periodontitis who attended the Department of Stomatology at a tertiary hospital in Chengde, China, between December 2025 and January 2026. Participants were recruited using purposive sampling. Interviews were conducted in person, and data were analyzed using qualitative content analysis guided by the COM-B model. Themes and sub-themes were identified through an iterative and collaborative coding process conducted by two trained researchers. Three main themes and eleven sub-themes were identified, reflecting barriers and support needs related to oral health behaviors. Within the capability domain, barriers included insufficient disease knowledge and information literacy, inadequate skills in using oral hygiene tools, and physical limitations. Within the opportunity domain, barriers included constraints related to objective resources and life circumstances and unsupportive social norms, while participants expressed support needs for professional and social support. Within the motivation domain, barriers included negative behavioral experiences, concerns about social judgment, and lack of self-efficacy, whereas perceived benefits and disease awareness and the desire to preserve oral health supported sustained oral health behaviors. Patients with periodontitis experience interconnected barriers and support needs across capability, opportunity, and motivation domains. These qualitative findings provide evidence to inform the development of tailored oral health behavior interventions.

PMID 42668984
Read full article →
PubMedPakistan journal of medical sciences2026-08-30

Prognostic value of a non-contrast CT-based radiomics model in patients with Type-B aortic dissection after thoracic endovascular aortic repair.

Zou Jiajun J, Shi Xinyi X, Ni Jianqi J, Jin Qin Q et al.

To explore the value of a non-contrast computed tomography (CT)-based radiomics model in predicting adverse prognosis in patients with type B aortic dissection (TBAD) after thoracic endovascular aortic repair (TEVAR). A retrospective analysis included data from 107 patients with TBAD undergoing TEVAR at the First Hospital of Jiaxing from January 2010 to May 2024. Patients were randomly divided into a training (n=86) and a validation cohort (n=21) at an 8:2 ratio. Radiomic features were extracted from non-contrast CT images to build a radiomic model. Univariate and multivariate logistic regression analyses identified independent clinical risk factors for constructing a clinical model. Lasso regression was used for data dimensionality reduction and model building. A clinical-radiomic model was established by integrating clinical risk factors with radiomic features. The discriminative ability, calibration, and clinical utility of the three models were evaluated using ROC curves (specificity and sensitivity), calibration curves, and clinical decision curve analysis (DCA), respectively. Ten radiomic features were selected in the training cohort. Clinical, radiomic, and clinical-radiomic models were generated using eight machine learning algorithms and exhibited good predictive performance. The clinical-radiomic model had the highest AUC values (0.943 in the training cohort, 0.875 in the validation cohort) compared to the clinical and radiomic models. Calibration curves and the Hosmer-Lemeshow test confirmed good calibration of all three models in both sets. DCA revealed that the nomogram model provided favorable clinical net benefits within a certain threshold range. A non-contrast CT-based radiomics machine learning model has high value for predicting adverse prognosis after TEVAR.

PMID 42668935
Read full article →
PubMedAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026-08-30

CD9+ B Cells Induce T Follicular Helper Cell Apoptosis to Regulate Germinal Center Regression.

Liao Wenjing W, Song Lijuan L, Xu Meiqian M, Liang Tianhao T et al.

Adenoid hypertrophy (AH) is associated with excessive proliferation of germinal center B (GC-B) cells, yet the mechanisms underlying GC regression and termination remain poorly understood. This study used single-cell RNA sequencing (scRNA-seq) to profile the cellular composition of GC-B cells in AH. A unique subset of GC-B cells expressing CD9 was identified through comprehensive scRNA-seq, flow cytometry, and Mass cytometry (CyToF) analyses, with subsequent studies assessing the roles of CD9 and FOXP1 in GC-B cell differentiation and apoptosis pathways. CD9+ B cells were detected throughout GC-B cell development and were regulated by FOXP1. These cells also exhibited activation of cell death-related pathways, particularly during adenoid development. AH samples showed an increase in T follicular helper (Tfh) cells, accompanied by a reduction in CD9+ B cells. In Cd9 knockout mice, CD9 deficiency led to a significant decrease in serum IgG levels. Further analysis revealed that CD9+ B cells promoted Tfh cell apoptosis via pathways such as ALCAM-CD6. CD9+ B cells may regulate GC-B cell regression by inducing Tfh cell apoptosis, and FOXP1 may play a role in their differentiation. These findings clarify mechanisms of GC degeneration and termination, offering potential targets for AH treatment.

PMID 42669617
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about amphotericin B